Findings

What do systematic reviews say?

1,655 questions · 1,751 findings · 147 reviews · Pain, Palliative and Supportive Care

Sort:Best matchNewestHighest certainty Download CSV

No studies found 361 · 20.6%GRADE not reported 87 · 5%Very low 625 · 35.7%Low 367 · 21%Moderate 232 · 13.2%High 79 · 4.5%

Summary of findings: liposomal bupivacaine vs bupivacaine

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · aged 18 years and older undergoing elective surgery at any surgical site

1 finding from 1 review

Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 134 participants
Very low

Summary of findings: liposomal bupivacaine vs bupivacaine

Time to first postoperative opioid dose over initial 72 hours · aged 18 years and older undergoing elective surgery at any surgical site

The review found no eligible studies for this question.

1 finding from 1 review

Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: liposomal bupivacaine vs bupivacaine

Total postoperative opioid consumption over first 72 hours · aged 18 years and older undergoing elective surgery at any surgical site

1 finding from 1 review

Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 134 participants
Very low

Summary of findings: liposomal bupivacaine vs bupivacaine

Percentage of participants not requiring postoperative opioids over initial 72 hours · aged 18 years and older undergoing elective surgery at any surgical site

1 finding from 1 review

Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 134 participants
Very low

Summary of findings: liposomal bupivacaine vs bupivacaine

Incidence of adverse events within 30 days of surgery · aged 18 years and older undergoing elective surgery at any surgical site

1 finding from 1 review

Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 583 participants
Moderate

Summary of findings: liposomal bupivacaine vs placebo

Serious adverse events · aged 18 years and older undergoing elective surgery at any surgical site

1 finding from 1 review

Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 382 participants
Low

Summary of findings: liposomal bupivacaine vs placebo

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · aged 18 years and older undergoing elective surgery at any surgical site

The review found no eligible studies for this question.

1 finding from 1 review

Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: liposomal bupivacaine vs placebo

Time to first postoperative opioid dose over initial 72 hours · aged 18 years and older undergoing elective surgery at any surgical site

1 finding from 1 review

Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 382 participants
Low

Summary of findings: liposomal bupivacaine vs placebo

Total postoperative opioid consumption over first 72 hours · aged 18 years and older undergoing elective surgery at any surgical site

1 finding from 1 review

Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 189 participants
Very low

Summary of findings: liposomal bupivacaine vs placebo

Percentage of participants not requiring postoperative opioids over initial 72 hours · aged 18 years and older undergoing elective surgery at any surgical site

1 finding from 1 review

Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 382 participants
Very low

Summary of findings: liposomal bupivacaine vs placebo

Incidence of adverse events within 30 days of surgery · aged 18 years and older undergoing elective surgery at any surgical site

1 finding from 1 review

Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 382 participants
Low

Summary of findings: liposomal bupivacaine vs bupivacaine

Cumulative pain score from the end of operation (0 hours) to 72 hours (NRS 0 to 10) · aged 18 years and older undergoing elective surgery at any surgical site

1 finding from 1 review

Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 379 participants
Very low

Summary of findings: liposomal bupivacaine vs bupivacaine

Serious adverse events · aged 18 years and older undergoing elective surgery at any surgical site

1 finding from 1 review

Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 583 participants
Moderate

Morphine vs placebo

Reported outcomes approximating to 30% reduction in pain · adults with neuropathic pain

1 finding from 1 review

Morphine for chronic neuropathic pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
62 participants
Very low

Morphine vs placebo

At least 50% reduction in pain · adults with neuropathic pain

1 finding from 1 review

Morphine for chronic neuropathic pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
62 participants
Very low

Morphine vs placebo

Patient Global Impression of Change much or very much improved · adults with neuropathic pain

1 finding from 1 review

Morphine for chronic neuropathic pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Morphine vs placebo

Any pain‐related outcome (moderate pain improvement) · adults with neuropathic pain

It is very uncertain whether morphine changes any pain‐related outcome (moderate pain improvement) compared with placebo (very low certainty).

1 finding from 1 review

Morphine for chronic neuropathic pain in adults 2017 · Cochrane Headline outcomes only
RD 0.27 [0.16, 0.38]
4 studies · 263 participants
Very low

Morphine vs placebo

Serious adverse events · adults with neuropathic pain

1 finding from 1 review

Morphine for chronic neuropathic pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 289 participants
Very low

Morphine vs placebo

Death · adults with neuropathic pain

1 finding from 1 review

Morphine for chronic neuropathic pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 289 participants
Very low

Morphine vs placebo

Any adverse event · adults with neuropathic pain

1 finding from 1 review

Morphine for chronic neuropathic pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 289 participants
Very low